Immuron Management

Management criteria checks 3/4

We currently do not have sufficient information about the CEO.

Key information

Steve Lydeamore

Chief executive officer

AU$599.1k

Total compensation

CEO salary percentage	72.7%
CEO tenure	2.3yrs
CEO ownership	n/a
Management average tenure	5.8yrs
Board average tenure	5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Steve Lydeamore's remuneration changed compared to Immuron's earnings?
Date	Total Compensation	Salary	Company Earnings
Jun 30 2024	AU$599k	AU$436k	-AU$7m
Mar 31 2024	n/a	n/a	-AU$5m
Dec 31 2023	n/a	n/a	-AU$4m
Sep 30 2023	n/a	n/a	-AU$4m
Jun 30 2023	AU$584k	AU$415k	-AU$4m
Mar 31 2023	n/a	n/a	-AU$3m
Dec 31 2022	n/a	n/a	-AU$3m
Sep 30 2022	n/a	n/a	-AU$3m
Jun 30 2022	AU$781k	AU$6k	-AU$3m

Compensation vs Market: Steve's total compensation ($USD403.68K) is about average for companies of similar size in the German market ($USD494.42K).

Compensation vs Earnings: Steve's compensation has increased whilst the company is unprofitable.

CEO

Steve Lydeamore (56 yo)

2.3yrs

Tenure

AU$599,135

Compensation

Mr. Steven George Lydeamore, also known as Steve, MBA, CPA, serves as Chief Executive Officer at Immuron Limited since June 27, 2022. He served as the Chief Executive Officer of Anatara Lifesciences Limite...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Steven Lydeamore	Chief Executive Officer	2.3yrs	AU$599.14k	no data
Jerry Kanellos	Chief Operating Officer	9.3yrs	AU$359.25k	0.15% A$ 17.1k
Flavio Palumbo	Chief Commercial Officer	1.9yrs	AU$347.61k	no data
Phillip Hains	CFO & Company Secretary	11.5yrs	no data	0.36% A$ 42.0k
David Lyon	Head of Marketing	no data	no data	no data

5.8yrs

Average Tenure

59.5yo

Average Age

Experienced Management: ANWA's management team is seasoned and experienced (5.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Glenn Tillotson	Member of Advisory Board	no data	no data	no data
Jeannette Joughin	Independent Non-Executive Director	less than a year	AU$7.55k	no data
Daniel Pollock	Independent Non-Executive Director	12yrs	AU$127.65k	0.36% A$ 42.1k
Paul Brennan	Independent Non-Executive Chairman	2.6yrs	AU$153.60k	no data
Dena Lyras	Member of Advisory Board	no data	no data	no data
Ravi Savarirayan	Independent Non-Executive Director	7.5yrs	AU$75.00k	0.39% A$ 45.1k
Sahil Khanna	Member of Advisory Board	no data	no data	no data
Paul Feuerstadt	Member of Advisory Board	no data	no data	no data
Teena Chopra	Member of Advisory Board	no data	no data	no data

5.0yrs

Average Tenure

63yo

Average Age

Experienced Board: ANWA's board of directors are considered experienced (5 years average tenure).

Immuron Management

Management criteria checks 3/4

Key information

Recent management updates

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited, Annual General Meeting, Oct 28, 2022

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Recent updates

Immuron Limited Announces NMRC Reports Results for Campylobacter Clinical Study

Immuron Limited has filed a Follow-on Equity Offering in the amount of $2.069083 million.

Immuron Requests Pre-IND Meeting for IMM-529 with FDA Filing

Immuron Limited Appoints Jeannette Joughin as Director

Immuron Limited Announces Resignation of Roger Aston as Non-Executive Director

Immuron Limited Announces Positive Results Support Travelan Progress to Phase 3 Clinical Trials in the US

Immuron Limited Clinical Trials Update

Immuron Announces First Patients Enrolled in Campylobacter Challenge Clinical Study

Immuron Limited, Annual General Meeting, Nov 21, 2023

Immuron Limited Announces Travelan® Clinical Study Cohort 2 Commences

Immuron Limited Announces First Patients Enrolled in Travelan® Clinical Study

Immuron Limited Initiates Recruitment of Travelan Clinical Study

Immuron Limited Announces US Food and Drug Administration Removed Clinical Hold on New Campylobacter ETEC Therapeutic Paves Way for Clinical Trial Initiation

Immuron US DoD Naval Medical Research Center Responds to FDA Clinical Hold for New Campylobacter ETEC Therapeutic

Immuron Limited Receives FDA Approval for Travelan IND Application

Immuron Limited Submits IND Application To FDA for Travelan

Immuron Limited, Annual General Meeting, Oct 28, 2022

Immuron Limited Provides Update on IMM-124E SARS-CoV-2 Research

Immuron Limited Provides Update on IND Application for Campylobacter ETEC Therapeutic

Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic

Immuron Limited Provides Update on the Planned Clinical Trial to Evaluate the Efficacy of Travelan and Two Third Party Non-Antibiotic Products in Travelers' Diarrhea

Immuron Limited Appoints Steven Lydeamore as Chief Executive Officer, effective June 27, 2022

Immuron Limited Announces Work on the Investigational New Drug Application to Evaluate the Efficacy of A Single Dose Regimen of Travelan

Immuron Limited Provides Monash University Research Update on SARS-CoV-2 Program

Immuron Limited Provides Update on Progress of the Anti-Viral Activity of IMM-124E

Immuron Limited Announces That the Naval Medical Research Center Has Completed the Characterisation of the Colostrum Harvested from Cows Immunized with the Experimental Vaccine Developed to Target Campylobacter and Enterotoxigenic E.Coli

Immuron Limited Announces US DoD NMRC Reports Positive Response to Vaccine

Immuron Limited Provides Shareholders and the Market with an Update on the Planned Clinical Programs in Travelers’ Diarrhea

Immuron Limited has completed a Follow-on Equity Offering in the amount of $20.000025 million.

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age